MMED:CC News and Press, MIND MEDICINE INC. From 05/02/23

Files Definitive Proxy Materials in Connection with June 15, 2023 Annual Meeting Board’s Nominees Possess Essential Pharmaceutical Industry, Capital Allocation and Corporate Governance Experience Needed to Drive Company’s Success at Pivotal Moment – With Two Key Clini...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Thursday, May 4, ...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management tea...

Interest in psychedelics has increased these last few years, mainly as a result of numerous studies that have found that the substances possess a range of medical benefits. The decriminalization of psychedelics is also said to benefit society at large, with improvements being seen in public h...

Presents Highly Qualified Slate of Director Nominees, Including Five Incumbent Board Members and New Independent Candidate David W. Gryska Highlights Significant Positive Momentum to Advance R&D Pipeline and Enhance Shareholder Value Discloses FCM MM HOLDINGS’ Intent to...

– Primary endpoint achieved statistically significant improvement in MDD symptoms – – Confirmation of activity of lysergide in brain health disorders with direct relevance to MindMed’s MM-120 program in Generalized Anxiety Disorder (GAD) – ȁ...

The next few decades will likely see psychedelic treatments go from relative obscurity to playing center stage in the psychiatric space. After decades of prohibition, psychedelics are now emerging as a potential alternative to traditional mental health therapies amid a surge in psychedelic rese...

A growing body of scientific literature has revealed that psychedelic drugs such as ketamine, MDMA and psilocybin may have therapeutic potential. Researchers have found in recent years that these hallucinogens may be able to alleviate the symptoms of certain mental health disorders when accompa...

Psychedelics are poised to play a significant role in the evolution of the psychiatric industry . Hallucinogenics have revealed in several studies that they are capable of treating a variety of mental health disorders with minimal side effects. Researchers have found that psychedelics such a...

– Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 – – Company to initiate first clinical trial of MM-402 in 2023 – – Cash and cash equivalents of $142.1 million at December 31, 202...